A pilot prospective , double-blind , randomized study was conducted to evaluate the ordinary dose of pitavastatin ( 2mg daily ) or atorvastatin ( 10mg daily ) treatment for 12weeks on circulating EPCs in patients with cardiovascular risk such as hypercholesterolemia and type 2 diabetes mellitus ( T2DM ) .